The Price of Global Health is the first book of its kind: an in-depth but straightforward exploration of the pharmaceutical pricing strategy process, its underlying market access, general business and ethical considerations, and its implications for payers, physicians and patients. It is a much needed and invaluable resource for anybody interested, involved in or affected by the development, funding and use of prescription drugs. In particular, it is of critical importance to pharmaceutical company executives and other leaders and professionals in commercialization and drug development, including marketing, business development, market access and pricing, clinical development, drug discovery, regulatory affairs, health outcomes, market research and public affairs.
Every four minutes, over 50 children under the age of five die. In the same four minutes, 2 mothers lose their lives in childbirth. Every year, malaria kills nearly 1.2 million people, despite the fact that it can be prevented with a mosquito net and treated for less than $1.50. Sadly, this list goes on and on. Millions are dying from diseases that we can easily and inexpensively prevent, diagnose, and treat. Why? Because even though we know exactly what people need, we just can’t get it to them. They are dying not because we can’t solve a medical problem but because we can’t solve a logistics problem. In this profoundly important book, Eric G. Bing and Marc J. Epstein lay out a solution: a new kind of bottom-up health care that is delivered at the source. We need microclinics, micropharmacies, and microentrepreneurs located in the remote, hard-to-reach communities they serve. By building a new model that “scales down” to train and incentivize all kinds of health-care providers in their own villages and towns, we can create an army of on-site professionals who can prevent tragedy at a fraction of the cost of top-down bureaucratic programs. Bing and Epstein have seen the model work, and they provide example after example of the extraordinary results it has achieved in Africa, Asia, and Latin America. This is a book about taking health care the last mile—sometimes literally—to prevent widespread, unnecessary, and easily avoided death and suffering. Pharmacy on a Bicycle shows how the same forces of innovation and entrepreneurship that work in first-world business cultures can be unleashed to save the lives of millions.
"Every year 9 million people are diagnosed with tuberculosis, every day more than 13,400 people are infected with AIDs, every 30 seconds malaria kills a child. Many people suffer and die young because they cannot access essential medicines. This book argues that people have a right to access these medicines and proposes some new Global Health Impact labelling, investment, and licensing strategies that encourage pharmaceutical companies to improve global health (global-health-impact.org/new). The idea is to rate these companies based on their medicines' impacts. Highly rated companies will get a Global Health Impact label to use on their products. Socially responsible investment companies and universities might also take the ratings into account in making investment or licensing decisions. After arguing that people do have a right to access essential medicines, this book explores this proposal, its philosophical justification, and its prospects for success"--
Claiming 1.5 million lives in 2015, tuberculosis is the world's most deadly infectious disease. Because of the population it overwhelmingly affects, however, pharmaceutical companies are uninterested in developing better drugs for the disease. Compound Solutions examines Product Development Partnerships (PDPs), which arose early in the twenty-first century to develop new drugs and vaccines for infectious diseases in low-income countries. Here, for the first time, is a sustained examination of PDPs: the work they do, the partnerships they form, their mission, and their underlying philosophy of addressing global health needs--with implications that extend well beyond tuberculosis. Focusing on two PDPs for tuberculosis--the Global Alliance for TB Drug Development (TB Alliance) and Aeras (a nonprofit focused on vaccine development)--Susan Craddock argues that PDPs do much more than product development. As innovative sites of humanitarian pharmaceutical production, they are contravening mainstream pharmaceutical production by tying drug and vaccine research to global health needs rather than shareholder demand. In largely untethering the profit incentive from pharmaceutical production, Craddock shows, PDPs exhibit more creative and efficient scientific practices, reshaping regulatory norms and implementing more ethical forms of clinical trials that enhance community engagement and capacity building. An unparalleled, interdisciplinary analysis of PDPs as politically, socially, scientifically, and economically innovative sites of pharmaceutical production, Compound Solutions is a must for readers in the fields of public health, science and technology studies, and medical social science.
This open access book explores ways to leverage information technology and machine learning to combat disease and promote health, especially in resource-constrained settings. It focuses on digital disease surveillance through the application of machine learning to non-traditional data sources. Developing countries are uniquely prone to large-scale emerging infectious disease outbreaks due to disruption of ecosystems, civil unrest, and poor healthcare infrastructure – and without comprehensive surveillance, delays in outbreak identification, resource deployment, and case management can be catastrophic. In combination with context-informed analytics, students will learn how non-traditional digital disease data sources – including news media, social media, Google Trends, and Google Street View – can fill critical knowledge gaps and help inform on-the-ground decision-making when formal surveillance systems are insufficient.
What can be done about the poor state of global health? How are global health challenges intimately linked to the global political economy and to issues of social justice? What are our responsibilities and how can we improve global health? Global Health and Global Health Ethics addresses these questions from the perspective of a range of disciplines, including medicine, philosophy and the social sciences. Topics covered range from infectious diseases, climate change and the environment to trade, foreign aid, food security and biotechnology. Each chapter identifies the ways in which we exacerbate poor global health and discusses what we should do to remedy the factors identified. Together, they contribute to a deeper understanding of the challenges we face, and propose new national and global policies. Offering a wealth of empirical data and both practical and theoretical guidance, this is a key resource for bioethicists, public health practitioners and philosophers.
There is a strong argument that people throughout the world have a right to receive the medicines they need in an appropriate, affordable, and timely way. Global Pharmaceutical Policy describes the laws, policies, and customs relating to the development and provision of medicines, identifies their strengths and weakness, and then proposes global solutions for getting things better. Here is a masterpiece written in a clear and elegant style. Together, Dukes and Abbott have experience and insight that are unrivalled. Joe Collier, Emeritus Professor of Medicines Policy, St George s, University of London, UK Pharmaceuticals play a central role in health care throughout the world. The pharmaceutical industry is beset with difficulties as increasing research and development expenditure yields fewer new treatments. Public and private budgets strain under the weight of high prices and limited access. The world s poor see little effort to address diseases prevalent in less affluent societies, while the world s wealthy are overusing prescription drugs, risking their health and wasting resources. As the global economic crisis exacerbates pressure on health care budgets, a new presidential administration in Washington, DC has committed to broad health care reform. These circumstances form the backdrop for this extraordinarily timely examination of the global system for the development, production, distribution and use of medicines. The authors are acknowledged experts in the fields of pharmaceutical law and policy, with many years experience advising governments, multilateral organizations and policy-makers on issues involving innovation, access and use of medicines. Supported by a team of independent scientists, doctors and lawyers, they take an insightful look at the issues surrounding global regulation of the pharmaceutical sector, and offer pragmatic suggestions for reform. This book will be of interest to government policy-makers, members of industry, healthcare professionals, teachers, students and lawyers in the fields of public health, intellectual property and international trade.
Encapsulating security : pharmaceutical defenses against biological danger -- Discovering a virus's achilles heel : flu fighting at molecular scale -- The pill always wins: Gilead Sciences, Roche and the birth of Tamiflu -- What a difference a day makes : the margin call for regulatory agencies -- Virtual blockbuster : bird flu and the pandemic of preparedness planning -- In the eye of the storm : global access, generics and intellectual property -- 'Ode to Tamiflu' : side effects, teenage 'suicides' and corporate liabilities -- Data backlash : Roche and Cochrane square up over clinical trial data -- 'To boldly go ... ' : pharmaceutical enterprises and global health security -- Epilogue : pharmaceuticals, security and molecular life
While serving as a physician overseas in resource-poor countries, Dr. James Chambers recognized the need for a practical, portable reference for non-specialist healthcare providers to orient them to common issues when serving in new situations, whether due to geography, austere environments, or complex humanitarian disasters. Field Guide to Global Health and Disaster Medicine draws on the experience, training, and perspectives of committed healthcare providers from diverse nations and backgrounds to provide the most essential information for maximum utility in the field—whether in a refugee camp, operating room, disaster response scene, or other demanding environment. - Helps providers prepare for service overseas, organize data to develop differential diagnoses, assimilate information on infectious and environmental diseases, and effectively serve the patients they will encounter. - Provides concise, easy-to-read coverage of how to approach a differential diagnosis for infectious diseases overseas; nutritional, sexual, and environmental conditions; surgical and anesthesia care; long-term and short-term systems-based challenges, and more. - Covers key topics such as Approach to Refugees and Internally Displaced Persons, Medical Response to Disasters, Mental Health in War and Crisis Regions, and Considerations for Pandemic Preparedness and Response. - Acknowledges the wide variance of different cultures, motives, resources, and limitations in the global health arena, and helps readers understand the factors which impact the efficacy and sustainability of care strategies.
